Trial Results

Protocol
Available Languages: English
Statistical Analysis Plan
Available Languages: English

Ravulizumab Versus Placebo in Adult Participants With Dermatomyositis

Study Identifier:
ALXN1210-DM-310
ClinicalTrials.gov Identifier:
EudraCT Identifier:
Sponsor:
Alexion Pharmaceuticals, Inc.
Study Contact Information:
N/A
Other

Study Details

Medical Condition
  • Unmapped
Study Drug
  • Drug: Ravulizumab
  • Drug: Placebo
Date
Nov 2021 - Oct 2023
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18+ years
Requirements Information
Sex
Female & Male
Age
18+ years

Study Details

Medical Condition
  • Unmapped
Study Drug
  • Drug: Ravulizumab
  • Drug: Placebo
Date
Nov 2021 - Oct 2023
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18+ years years
Requirements Information

Protocol Summary

This is a Phase 2/3, double-blind, randomized, placebo-controlled, parallel group, multicenter study to evaluate the efficacy, safety, pharmacokinetics, pharmacodynamics, and immunogenicity of ravulizumab in adult participants with dermatomyositis (DM).

Trial Locations

Location
Status
Location
Research Site
Irvine, California, United States, 92617
Status
N/A
Location
Research Site
Atlanta, Georgia, United States, 30322
Status
N/A
Location
Research Site
Chicago, Illinois, United States, 60637
Status
N/A
Location
Research Site
Fairway, Kansas, United States, 66205
Status
N/A
Location
Research Site
Baltimore, Maryland, United States, 21205
Status
N/A
Location
Research Site
Charleston, South Carolina, United States, 29425
Status
N/A